Citigroup Inc. Reduces Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Citigroup Inc. lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) by 31.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 90,013 shares of the company’s stock after selling 41,733 shares during the period. Citigroup Inc. owned approximately 0.12% of Day One Biopharmaceuticals worth $1,937,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. BlackRock Inc. grew its position in Day One Biopharmaceuticals by 29.5% during the 3rd quarter. BlackRock Inc. now owns 2,541,235 shares of the company’s stock worth $50,901,000 after purchasing an additional 578,511 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Day One Biopharmaceuticals by 2.6% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,094,913 shares of the company’s stock valued at $41,962,000 after acquiring an additional 53,569 shares during the last quarter. State Street Corp boosted its holdings in shares of Day One Biopharmaceuticals by 469.1% in the 3rd quarter. State Street Corp now owns 2,041,738 shares of the company’s stock valued at $40,896,000 after acquiring an additional 1,682,955 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 5,969.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,894,537 shares of the company’s stock valued at $33,912,000 after acquiring an additional 1,863,325 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $10,100,000. Hedge funds and other institutional investors own 86.08% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $12.06 on Friday. The company has a fifty day moving average of $13.55 and a two-hundred day moving average of $18.17. The stock has a market capitalization of $887.25 million, a PE ratio of -5.29 and a beta of -2.08. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last issued its earnings results on Monday, May 1st. The company reported ($0.59) EPS for the quarter, meeting analysts’ consensus estimates of ($0.59). Research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.47 earnings per share for the current year.

Insider Activity

In other news, CEO Jeremy Bender sold 12,500 shares of the stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $20.01, for a total value of $250,125.00. Following the completion of the sale, the chief executive officer now directly owns 1,174,276 shares in the company, valued at $23,497,262.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $18.05, for a total value of $180,500.00. Following the completion of the sale, the insider now owns 1,233,660 shares of the company’s stock, valued at $22,267,563. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeremy Bender sold 12,500 shares of the company’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $20.01, for a total transaction of $250,125.00. Following the completion of the sale, the chief executive officer now directly owns 1,174,276 shares of the company’s stock, valued at approximately $23,497,262.76. The disclosure for this sale can be found here. Insiders sold 27,251 shares of company stock worth $492,958 over the last three months. Insiders own 8.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on DAWN. Capital One Financial began coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, February 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. Bank of America cut shares of Day One Biopharmaceuticals from a “buy” rating to an “underperform” rating in a research note on Tuesday, April 25th. Oppenheimer assumed coverage on shares of Day One Biopharmaceuticals in a research note on Thursday, February 2nd. They issued a “market perform” rating for the company. Needham & Company LLC decreased their target price on shares of Day One Biopharmaceuticals from $48.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, April 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.57.

Day One Biopharmaceuticals Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.